Jeff Ajer
Board Member
Viridian Therapeutics, Inc.\DE (VRDN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jeff Ajer
Jeff Ajer is recorded as Board Member at Viridian Therapeutics, Inc.\DE (VRDN). Viridian Therapeutics, Inc.\DE reported in an 8-K filed June 24, 2025 that Jeff Ajer was appointed Class I director, effective June 20, 2025. Viridian Therapeutics, Inc.\DE reported in an 8-K filed April 7, 2025 that Jeff Ajer was appointed Class I director, effective April 7, 2025. The proxy statement of Biomarin Pharmaceutical Inc reports total compensation of $5,070,357 for Jeff Ajer in fiscal 2023, including a base salary of $669,231. Disclosed compensation is on record for 7 fiscal years. Jeff Ajer has spoken on 1 earnings call across 1 company, most recently for Biomarin Pharmaceutical Inc on November 5, 2020.
“Election of the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders:”
“On April 2, 2025, the Board of Directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), appointed Jeff Ajer to serve as a Class I director of the Company, effective as of April 7, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Biomarin Pharmaceutical Inc (BMRN)
Proxy statement
Start not stated–2024-04-09
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Viridian Therapeutics, Inc.\DE
Other people whose current roles at this company are on record from its filings.
- Lee Rauch CEO, COO, Board Member
- Scott Myers CEO, Board Member
- Stephen Mahoney CEO, Board Member
- Tomas Kiselak Chairman
- Seth Harmon CFO
- Jonathan Violin COO
- Thomas Beetham COO
- Lara Meisner General Counsel
- Kristian Humer Chief Accounting Officer
- Arlene M. Morris Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $669,231 | $5,070,357 |
| 2022 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $638,269 | $5,457,338 |
| 2021 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $610,000 | $4,985,408 |
| 2020 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $628,654 | $4,536,436 |
| 2019 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $580,192 | $6,344,322 |
| 2018 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $554,232 | $4,545,383 |
| 2017 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer | $524,231 | $4,568,302 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.